Grid computing in large pharmaceutical molecular modeling.
Most major pharmaceutical companies have employed grid computing to expand their compute resources with the intention of minimizing additional financial expenditure. Historically, one of the issues restricting widespread utilization of the grid resources in molecular modeling is the limited set of suitable applications amenable to coarse-grained parallelization. Recent advances in grid infrastructure technology coupled with advances in application research and redesign will enable fine-grained parallel problems, such as quantum mechanics and molecular dynamics, which were previously inaccessible to the grid environment. This will enable new science as well as increase resource flexibility to load balance and schedule existing workloads.
Claus
Brian L
BL
Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, USA. brian.claus@bms.com
Johnson
Stephen R
SR
D003198:Computer Simulation; D004345:Drug Industry / Q000639:trends*; D008958:Models, Molecular